| Revenue Growth | Total revenue $18.2 million; net product revenue up 2% sequentially. |
|---|---|
| Mgmt Confidence | High confidence in Zozi becoming ADC backbone; 2027 pivotal for growth. |
| Demand Visibility | Stabilization in China; volume expansion expected from NRDL inclusion next year. |
| Margin Trends | China commercial business remains profitable; R&D and SG&A expenses remained stable. |
| Op. Leverage | Disciplined cost structure and resource optimization initiatives implemented across the organization. |
| Pricing Power | Zejula maintained position despite volume-based pricing dynamics and competitive landscape. |
| Vol vs Price | Growth driven by new patient starts and volume expansion despite pricing pressures. |
| Segment Growth | Zejula and Vyvgart volumes grew sequentially; Nuzyra sales stronger than expected. |
| New Clients | Collaborations with Amgen and BI for T-cell engager combinations advancing rapidly. |
| Capex & Debt | Raised $250 million in equity; cash position $659.7 million as of September. |
| Regulatory | Potential US BLA submission for Zozi in 2027; EPNEC accelerated approval path. |
| Commentary | Transitioning from China-focused commercial entity to global innovative drug developer. |
| New Launches | ZL-1503 for atopic dermatitis; three additional oncology assets entering clinic 2027. |
Growth
Total revenue $18.2 million; net product revenue grew 2% sequentially showing China stabilization.
Outlook
Anticipate return to year-over-year product revenue growth in 2027 driven by NRDL.
Risks
Management used vague language regarding specific ORR thresholds required for FDA accelerated approval.
The company's earnings call, NASDAQ: ZLAB, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Zai Lab Ltd: key numbers
- Share price
- $23.47Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zai Lab Ltd
All →Zai Lab Director Richard Gaynor Buys $33.4K of Stock
Richard Gaynor, Director, bought 1,228 shares of Zai Lab Ltd at $27.19 a share, worth $33.4K in total on Nov 10, 2026. Shares held after the trade: 81,965 (+1.5%).
- Value
- $33.4K
- Shares
- 1,228
- Price
- $27.19
- Role
- Director
- Holding change
- +1.5%
- Trade date
- Nov 10, 2026
Zai Lab Q3 2026 Results: Net Loss of $46.1M, Loss Widens
Zai Lab Limited filed its Q3 2026 report as a large accelerated filer, reporting 1,124,448,350 ordinary shares outstanding as of October 31, 2026. The filing outlines significant risk factors related to its operations in mainland China, including regulatory uncertainties, manufacturing compliance, and geopolitical tensions.
- Key figure
- Net loss $46.1M
Zai Lab Financial Results
Zai Lab reported third quarter 2026 total revenues of $108.2 million, representing a 2% sequential increase in net product revenue. The company highlighted positive clinical data for its internally developed ADC, zocilurtatug pelitecan (zoci), in small cell lung cancer and expects 2027 to be a pivotal year with its first potential U.S. BLA submission.
- Term
- Q3 2026
“We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally. The strong first-line combination data for zocilurtatug pelitecan (zoci) presented at ESMO strengthen our confidence in its potential to become an ADC backbone of choice in small cell lung cancer.”
Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab
“This profile supports taking a standard chemotherapy-free regimen into a global Phase 3 study and gives us a strong foundation to build on with T-cell engager combinations. Our registrational programs in SCLC and neuroendocrine carcinomas are advancing toward readouts that could support our first U.S. BLA submission in 2027.”
Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab
Zai Lab Capital Raise of $250M
Zai Lab Limited entered into a securities purchase agreement with accredited investors for a private placement (PIPE) of 11,340,000 American depositary shares (ADSs). The company expects to receive gross proceeds of approximately $250 million to fund pipeline development and general corporate purposes. The ADSs are priced at $22.04 each, and the company has agreed to file a registration statement for the resale of these securities.
- Value
- $250M